SANGAMO THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $39.6M | $57.8M | $176.2M | $111.3M | $110.7M | $118.2M | $102.4M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $112.7M | $111.5M | $234.1M | $249.9M | $230.8M | $180.6M | $145.9M |
| SG&A Expense | — | $34.9M | $44.7M | $61.2M | $62.7M | $63.2M | $67.1M | $61.7M |
| Operating Income | — | $-121.2M | $-104.0M | $-274.0M | $-201.3M | $-183.3M | $-129.6M | $-105.2M |
| Operating Margin | — | -306.5% | -179.9% | -155.5% | -180.8% | -165.6% | -109.6% | -102.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-123.5M | $-98.1M | $-262.9M | $-191.8M | $-178.0M | $-120.8M | $-95.4M |
| Income Tax Expense | — | $-568.0K | $-167.0K | $-5.1M | $429.0K | $306.0K | $345.0K | $0 |
| Net Income | — | $-122.9M | $-97.9M | $-257.8M | $-192.3M | $-178.3M | $-121.0M | $-95.2M |
| Net Margin | — | -310.8% | -169.4% | -146.3% | -172.8% | -161.1% | -102.4% | -92.9% |
| EPS (Basic) | — | $-0.44 | $-0.49 | $-1.48 | $-1.25 | $-1.23 | $-0.90 | $-0.85 |
| EPS (Diluted) | — | $-0.44 | $-0.49 | $-1.48 | $-1.25 | $-1.23 | $-0.90 | $-0.85 |
| Shares Outstanding (Basic) | 414.3M | 280.2M | 201.7M | 174.4M | 154.3M | 144.6M | 134.4M | 112.1M |
| Shares Outstanding (Diluted) | 414.3M | 280.2M | 201.7M | 174.4M | 154.3M | 144.6M | 134.4M | 112.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |